Headlands Technologies LLC Acquires 11,745 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Headlands Technologies LLC grew its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 339.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,206 shares of the company’s stock after acquiring an additional 11,745 shares during the period. Headlands Technologies LLC’s holdings in Teva Pharmaceutical Industries were worth $215,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Wellington Management Group LLP boosted its holdings in Teva Pharmaceutical Industries by 42.2% in the 3rd quarter. Wellington Management Group LLP now owns 344,587 shares of the company’s stock worth $3,515,000 after buying an additional 102,261 shares during the period. Nordea Investment Management AB boosted its holdings in Teva Pharmaceutical Industries by 1.7% in the 4th quarter. Nordea Investment Management AB now owns 89,136 shares of the company’s stock worth $931,000 after buying an additional 1,521 shares during the period. Gateway Investment Advisers LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 28.6% during the 4th quarter. Gateway Investment Advisers LLC now owns 41,882 shares of the company’s stock valued at $437,000 after purchasing an additional 9,312 shares during the last quarter. SG Americas Securities LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 31.7% during the 4th quarter. SG Americas Securities LLC now owns 544,878 shares of the company’s stock valued at $5,689,000 after purchasing an additional 131,043 shares during the last quarter. Finally, AustralianSuper Pty Ltd boosted its holdings in shares of Teva Pharmaceutical Industries by 18.8% during the 4th quarter. AustralianSuper Pty Ltd now owns 9,039,070 shares of the company’s stock valued at $94,368,000 after purchasing an additional 1,431,671 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Wall Street Analyst Weigh In

TEVA has been the subject of several research reports. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Monday, May 20th. Jefferies Financial Group increased their price objective on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, June 27th. Piper Sandler restated an “overweight” rating and set a $20.00 target price (up from $19.00) on shares of Teva Pharmaceutical Industries in a research report on Monday, May 13th. Bank of America upped their target price on shares of Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the company a “buy” rating in a research report on Thursday, May 30th. Finally, UBS Group upped their target price on shares of Teva Pharmaceutical Industries from $22.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, July 10th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $18.56.

Insider Transactions at Teva Pharmaceutical Industries

In other news, insider Vikki L. Conway sold 15,219 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $16.74, for a total transaction of $254,766.06. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, insider Vikki L. Conway sold 15,219 shares of the stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $16.74, for a total transaction of $254,766.06. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Roberto Mignone sold 519,000 shares of the stock in a transaction that occurred on Tuesday, June 18th. The shares were sold at an average price of $17.03, for a total transaction of $8,838,570.00. Following the transaction, the director now owns 981,000 shares in the company, valued at $16,706,430. The disclosure for this sale can be found here. Over the last three months, insiders have sold 549,719 shares of company stock valued at $9,353,736. 0.55% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Trading Down 1.1 %

Teva Pharmaceutical Industries stock traded down $0.19 during midday trading on Tuesday, reaching $16.89. The stock had a trading volume of 5,639,687 shares, compared to its average volume of 10,347,366. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.20. Teva Pharmaceutical Industries Limited has a 52-week low of $7.95 and a 52-week high of $17.69. The firm has a market cap of $19.13 billion, a price-to-earnings ratio of -41.95, a price-to-earnings-growth ratio of 1.64 and a beta of 0.90. The company has a fifty day moving average of $16.60 and a 200 day moving average of $14.15.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, May 8th. The company reported $0.46 earnings per share for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.03). Teva Pharmaceutical Industries had a positive return on equity of 37.33% and a negative net margin of 2.88%. The firm had revenue of $3.82 billion during the quarter, compared to analysts’ expectations of $3.70 billion. On average, analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.32 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.